

NEWS RELEASE

**License Transfer from Solasia to Lee's Pharm**  
**for the Sales Promotion of Sancuso® and episil® in three cities in China**

TOKYO & HONG KONG, June 30, 2022 - Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter "Solasia") and Lee's Pharmaceutical Holdings Limited (SEHK stock code: 0950, Headquarters: Hong Kong, Executive Managing Director: Lee lalertsuphakun Wanee, hereinafter "Lee's Pharm") jointly announced today that Solasia and Lee's Pharm have entered into a business transfer agreement for the rights of promoting, distributing and selling of Sancuso® and episil® in Beijing, Shanghai and Guangzhou in the People's Republic of China.

Sancuso® is a transdermal granisetron patch for patients suffering from chemotherapy-induced nausea and vomiting (CINV). episil® oral liquid is indicated for managing pain associated with oral mucositis caused by chemotherapy or radiotherapy. Both products are mainly aimed at reducing/controlling the side effects caused by cancer treatments. Since 2019, Sancuso® and episil® have been launched in Mainland China and are listed on the Chinese clinical practice guidelines.

Solasia has developed and obtained approval for both Sancuso® and episil® and has been promoting in Beijing, Shanghai, and Guangzhou. Also, Lee's Pharm has been selling in other regions of the Mainland China since 2019. Solasia has decided to transfer the sales business to achieve more efficient sales coverage by unifying the sales network under Lee's Pharm. Solasia will retain the right to continue supplying products to Lee's Pharm.

The transfer of this business is scheduled for August 1, 2022.